HOME >> MEDICINE >> NEWS
ReQuip cuts risk of dyskinesias by 15-fold in early Parkinson's disease

Vancouver, Canada - A landmark, multinational, 5-year study shows that the dopamine-agonist ReQuip® (ropinirole hydrochloride, SmithKline Beecham) is associated with a much lower incidence of dyskinesias than L-dopa, and has comparable efficacy to L-dopa in the management of early Parkinson's Disease. The results of this exciting study are released today for the first time at the XIII International Congress on Parkinson's Disease (ICPD), Vancouver, 24-28 July, 1999.

"This landmark study should affect the future management of Parkinson's Disease. The data demonstrate that ropinirole is a first-line option for the initial treatment of early Parkinson's Disease," commented lead author of the study, Professor Olivier Rascol, Professor of Pharmacology at the Centre Hospitalier Universitaire, Toulouse, France.

"This is important news for patients, as we can now hope for good control of their symptoms with less risk of dyskinesias," concluded Dr Donald Calne, Chairman of the ICPD, and Director of the Neurodegenerative Disorders Centre, University of British Columbia, Vancouver, Canada.

The 268 patients participating in this double-blind controlled study, conducted in Europe, Israel and Canada, were randomised to receive either ReQuip® or L-dopa -- the current standard therapy. Both treatment groups were allowed to receive supplementary L-dopa if required.

The study demonstrated that the probability (odds ratio) of developing dyskinesias was 3.8 times higher for patients receiving L-dopa (incidence 46%) than for patients receiving ReQuip®, either alone or with additional L-dopa (incidence 20%). In patients who completed the trial on ReQuip® alone, the benefit was found to be even greater, with the relative probability of dyskinesias 15.2 times higher in the L-dopa group (incidence 36%) than the ReQuip® group (incidence 5%).

Over the 5-year study period, both groups of patients experienced similar control of their symptoms. A
'"/>

Contact: Kate Davies (Vancouver)
alexa@meditech.co.uk
44-780-840-345
MediTech Media Ltd.
26-Jul-1999


Page: 1 2

Related medicine news :

1. Clozapine effective for controlling dyskinesias in people with severe Parkinsons
2. New marker for early diagnosis of kidney failure identified
3. English-speaking Hispanic youth more likely to have sex early
4. Inpatient smoking cessation counseling is associated with early differences in mortality
5. Study finds no reason for expectant mothers to shy away from early epidurals
6. No increase in C-sections when epidural analgesia given early in labor
7. Radiologists offer non-surgical treatment for early-stage liver cancer
8. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
9. A new method for early detection of disease outbreaks
10. UCLA study: Nearly a third of drug ads in medical journals contain no references for medical claims
11. Morbidly obese pay nearly twice as much for health care

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: ReQuip cuts risk dyskinesias fold early Parkinson disease

(Date:11/24/2014)... 2014 The typical American diet includes ... ingredients. Consistently consuming a diet high in calories and ... excess fat that typically accumulate around the internal organs ... ugly head in the form of love handles, beer ... the decision to rid themselves of the burden of ...
(Date:11/24/2014)... CO, and Philadelphia, PA (PRWEB) November 24, 2014 ... provider of care coordination and disease management services ... has chosen to implement Essette’s Medical Management software ... new Essette SaaS platform in a program to ... Essette suite includes Population Health Management, Care Management, ...
(Date:11/24/2014)... San Diego, California (PRWEB) November 24, 2014 ... the San Diego Fertility Center, recently appeared on NBC to ... preservation option. Egg freezing has been trending in the news ... covering this expensive procedure for women. , “[The ... the women who are on a career hot path.” Says ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... For the coming special Friday, Tidebuy, a ... great promotion for many products, especially the beautiful colored ... best choice with amazing discounts, up to 90% off. ... It is easy to buy colored wedding dresses in ... is also famous for delicate craftsmanship, elegant style and ...
Breaking Medicine News(10 mins):Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Beautiful Wedding Dresses Available at Popular B2C Company Tidebuy 2
(Date:11/22/2014)... Statistics released from a number of organizations ... during the holidays, beginning with Thanksgiving eve, which is ... The data, highlighted in an Infographic ... of their annual Sober Days for the Holidays ... drinking and increased rates of DUI injuries and deaths ...
(Date:11/22/2014)... 2014 Many power shifts are occurring ... of patients in the biopharmaceutical market is impacting ... than ever, understanding how to effectively acquire, convert, ... essential. According to recent research ... spent about two-thirds of their patient-focused dollars on ...
(Date:11/21/2014)... DIEGO , Nov. 21, 2014  Tandem ... TNDM ), a medical device company and manufacturer ... announced a partnership with Tidepool, a non-profit dedicated ... open source software platform that increases diabetes data ... Tidepool Platform, which is currently under development, to ...
Breaking Medicine Technology:Alarming Stats Show Holiday Drinking an Issue for Many 2New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
Cached News: